www.sciencedirect.com
Open in
urlscan Pro
162.159.130.81
Public Scan
Submitted URL: https://doi.org/10.1016/j.ctim.2014.11.003
Effective URL: https://www.sciencedirect.com/science/article/abs/pii/S096522991400185X?via%3Dihub
Submission: On January 26 via api from US — Scanned from DE
Effective URL: https://www.sciencedirect.com/science/article/abs/pii/S096522991400185X?via%3Dihub
Submission: On January 26 via api from US — Scanned from DE
Form analysis
1 forms found in the DOMGET /search#submit
<form class="QuickSearch" action="/search#submit" method="get" aria-label="form"><input type="search" class="query" aria-label="Search ScienceDirect" name="qs" placeholder="Search ScienceDirect"><button class="button button-primary" type="submit"
aria-label="Submit search"><span class="button-text"><svg role="img" focusable="false" viewBox="0 0 100 128" height="20" width="18.75" class="icon icon-search" aria-label="Search">
<title>Search</title>
<path
d="m19.22 76.91c-5.84-5.84-9.05-13.6-9.05-21.85s3.21-16.01 9.05-21.85c5.84-5.83 13.59-9.05 21.85-9.05 8.25 0 16.01 3.22 21.84 9.05 5.84 5.84 9.05 13.6 9.05 21.85s-3.21 16.01-9.05 21.85c-5.83 5.83-13.59 9.05-21.84 9.05-8.26 0-16.01-3.22-21.85-9.05zm80.33 29.6l-26.32-26.32c5.61-7.15 8.68-15.9 8.68-25.13 0-10.91-4.25-21.17-11.96-28.88-7.72-7.71-17.97-11.96-28.88-11.96s-21.17 4.25-28.88 11.96c-7.72 7.71-11.97 17.97-11.97 28.88s4.25 21.17 11.97 28.88c7.71 7.71 17.97 11.96 28.88 11.96 9.23 0 17.98-3.07 25.13-8.68l26.32 26.32 7.03-7.03">
</path>
</svg></span></button><input type="hidden" name="origin" value="article"><input type="hidden" name="zone" value="qSearch"></form>
Text Content
JavaScript is disabled on your browser. Please enable JavaScript to use all the features on this page. Skip to main content Skip to article ScienceDirect * Journals & Books * Help * Search RegisterSign in PDF View PDF * Access through your institution * Purchase PDF Search ARTICLE PREVIEW * Abstract * Introduction * Section snippets * References (25) * Cited by (5) * Recommended articles (6) COMPLEMENTARY THERAPIES IN MEDICINE Volume 23, Issue 4, August 2015, Pages 612-616 A CASE-CONTROL, MONO-CENTER, OPEN-LABEL, PILOT STUDY TO EVALUATE THE FEASIBILITY OF THERAPEUTIC TOUCH IN PREVENTING RADIATION DERMATITIS IN WOMEN WITH BREAST CANCER RECEIVING ADJUVANT RADIATION THERAPY Author links open overlay panelJawaidYounusaPersonEnvelopeMichaelLockbOlgaVujovicbEdwardYubJitkaMaleccDavidD'SouzacLarryStittd Show moreNavigate Down PlusAdd to Mendeley ShareShare Cited ByCite https://doi.org/10.1016/j.ctim.2014.11.003Get rights and content SUMMARY BACKGROUND Therapeutic touch (TT) is a non-invasive commonly used complementary therapy. TT is based on the use of hand movements and detection of energy field congestion to correct imbalances. Improvement in subjective symptoms in a variety of clinical trials has been seen with TT. The effect of TT during radiotherapy for breast cancer is unknown. METHODS Women undergoing adjuvant radiation for Stage I/II breast cancer post conservative surgery were recruited for this cohort study. TT treatments were administered three times per week following radiation therapy. Feasibility was defined as an a priori threshold of 15 of 17 patients completing all TT treatments. The preventive effectiveness of TT was evaluated by documenting the ‘time to develop’ and the ‘worst grade of radiation’ dermatitis. Toxicity was assessed using NCIC CTC V3 dermatitis scale. Cosmetic rating was performed using the EORTC Breast Cosmetic Rating. The quality of life, mood and energy, and fatigue were assessed by EORTC QLQ C30, POMS, and BFI, respectively. The parameters were assessed at baseline, and serially during treatment. RESULTS A total of 49 patients entered the study (17 in the TT Cohort and 32 in the Control Cohort). Median age in TT arm was 63 years and in control arm was 59 years. TT was considered feasible as all 17 patients screened completed TT treatment. There were no side effects observed with the TT treatments. In the TT Cohort, the worst grade of radiation dermatitis was grade II in nine patients (53%). Median time to develop the worst grade was 22 days. In the Control Cohort, the worst grade of radiation dermatitis was grade III in 1 patient. However, the most common toxicity grade was II in 15 patients (47%). Three patients did not develop any dermatitis. Median time to develop the worst grade in the control group was 31 days. There was no difference between cohorts for the overall EORTC cosmetic score and there was no significant difference in before and after study levels in quality of life, mood and fatigue. CONCLUSION This study is the first evaluation of TT in patients with breast cancer using objective measures. Although TT is feasible for the management of radiation induced dermatitis, we were not able to detect a significant benefit of TT on NCIC toxicity grade or time to develop the worst grade for radiation dermatitis. In addition, TT did not improve quality of life, mood, fatigue and overall cosmetic outcome. INTRODUCTION Therapeutic Touch (TT) is the current term used for an ancient practice called the “laying of hands” commonly used in a variety of settings. However, this is a misnomer since the intervention does not necessarily require any direct patient touching. It is based on a belief that every living organism has an energy field around it that produces an aura. This energy field can go unbalanced when the living organism is sick and healers can feel and manipulate this energy field by movement of hands over the patient's body just like massaging the air few inches above the patient's body. This process usually lasts 10–20 min depending on the practitioner's ability to detect these imbalances and the amount of areas with energy congestion.1 This primal life energy imbalance can be corrected according to TT practitioners. Furthermore, this channeling of vital energy can assist healing; a concept common in Ayurvedic medicine and healing systems found in India, China, Japan, and Greece where it is called prana, chi, ki, or pneuma, respectively.1, 2 According to the Cochcrane Collaboration, TT was first popularized by Dr. Krieger, a research nursing professor at New York University. A literature search using the MESH heading ‘therapeutic touch’ identifies 847 articles with 178 published within the last 5 years.3 TT at present is taught in 75 schools and universities and at 95 health care facilities in North America.4 Training is available in over 70 countries through institutions such as The American Nurses Association.4 There are no known side effects related to the use of TT. Most of the previous trials on TT have demonstrated subjective symptom improvement in a variety of clinical situations, including anxiety, pain and other related symptoms. The rationale for this study stemmed from clinical trials, which demonstrated improvement in wound healing with TT.2, 5 Relative to many alternative therapies, the demonstration of a quantifiable objective response is an interesting and impressive aspect of TT that calls for further investigation. Radiation induced dermatitis is a common problem in a significant proportion of patients treated with radiation. In addition, it is a quantifiable complication, easily observed and graded according to National Cancer Institute criteria for toxicity. Therefore, we opted to investigate TT to assess its ability to prevent radiation dermatitis associated with adjuvant radiation therapy for early breast cancer. SECTION SNIPPETS PATIENT SELECTION A single institution, ethics review board approved, prospective case-cohort study was conducted in patients with histo-pathologically or cytologically confirmed diagnosis of breast cancer, scheduled to receive adjuvant tangent radiation therapy as outpatients at the London Regional Cancer Program, London, Ontario. Female patients between 18 and 80 years of age at the time of enrollment and who had completed lumpectomy and sentinel lymph node biopsy or axillary lymph node dissection were RESULTS From a total of 49 patients, the TT group comprised of 17 patients with the median age of 63 years, while 32 patients were included in the control group with median age of 59 years. All patients in both groups had lumpectomy. The details on tumor size, lymph node evaluation, hormone receptor and Her-2Neu status are summarized in Table 1. The Eastern Cooperative Oncology Group (ECOG) performance status was 0–1 in all the patients. Our primary objective was feasibility of introducing this DISCUSSION Therapeutic touch was brought to mainstream medical attention by Dolores Krieger, Ph.D., R.N., a faculty member at New York University's Division of Nursing, who began TT in the early 1970s. Soon afterwards TT was learned and used by nurses as an adjunct to patient care. Interestingly, the first phase of research began in the 1960s with studies examining the effects of TT on plant growth and wound healing in mice.21 However in the 1970s Dora Kunz and Dolores Krieger were among the first to use CONCLUSIONS This study is the first evaluation of TT in patients with breast cancer using objective measures. Introduction of this alternative therapy into a comprehensive cancer clinic was feasible and acceptable. While there were no side effects observed, we were not able to detect a significant benefit of TT on NCIC toxicity grade or time to develop radiation dermatitis. In addition, TT did not improve quality of life, overall mood, fatigue and overall cosmetic outcome. CONFLICT OF INTEREST This is to certify that all authors have seen and approved the manuscript submitted and have no conflicts of interest. REFERENCES (25) * A.L. Schwartz et al. MEASUREMENT OF FATIGUE. DETERMINING MINIMALLY IMPORTANT CLINICAL DIFFERENCES J CLIN EPIDEMIOL (2002) * A. Trotti et al. CTCAE V 3.0: DEVELOPMENT OF A COMPREHENSIVE GRADING SYSTEM FOR THE ADVERSE EFFECTS OF CANCER TREATMENT SEMINRAD.ONC (2003) * D. Krieger THE THERAPEUTIC TOUCH: HOW TO USE YOUR HANDS TO HELP OR HEAL (1979) * D.P. O'Mathuna THERAPEUTIC TOUCH: WHAT COULD BE THE HARM? SCIENTIFIC REVIEW OF ALTERNATE MEDICINE (1998) * US National Library of Medicine. PubMed.Gov. Accessed August 15,... * D.P. O'Mathuna et al. THERAPEUTIC TOUCH FOR HEALING ACUTE WOUNDS COCHRANE DATABASE SYST REV (2014) * J.A. Astin et al. THE EFFICACY OF DISTANT HEALING: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS ANN INTERN MED (2000) * N.K. Aaronson et al. THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QLQ-C30: A QUALITY OF LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL TRIALS IN ONCOLOGY J NATL CANCER INST (1993) * J. Dancey et al. QUALITY OF LIFE SCORES: AN INDEPENDENT PROGNOSTIC VARIABLE IN A GENERAL POPULATION OF CANCER PATIENTS RECEIVING CHEMOTHERAPY. THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP QUAL LIFE RES (1997) * H.E. Niezgoda et al. A VALIDATION STUDY OF THE DOMAINS OF THE CORE EORTC QUALITY OF LIFE QUESTIONNAIRE QUAL LIFE RES (1993) G.I. Ringdal et al. TESTING THE EORTC QUALITY OF LIFE QUESTIONNAIRE ON CANCER PATIENTS WITH HETEROGENOUS DIAGNOSES QUAL LIFE RES (1993) F. Baker et al. A POMS SHORT FORM FOR CANCER PATIENTS: PYSCHOMETRIC AND STRUCTURAL EVALUATION PSYCHOONCOLOGY (2002) Navigate DownView more references CITED BY (5) * EFFECT OF THERAPEUTIC TOUCH ON SLEEP QUALITY AND ANXIETY IN INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE: A RANDOMIZED CONTROLLED TRIAL 2021, Complementary Therapies in Clinical Practice Show abstractNavigate Down The purpose is to determine the effect of therapeutic touch (TT) on the sleep quality and anxiety of individuals with chronic obstructive pulmonary (COPD) disease. 103 patients were randomized in to the two groups: the experimental group, and the control group. In this randomized control study, the patients with COPD in the experimental group were given TT for 10 min between 18:00 and 20:00, one session every day for three consecutive days. When the experimental group was compared to control group following the intervention, the decrease in the levels of anxiety (p < 0.001) and increase in the sleep quality (p < 0.001) were found to be significant. As a result of the study, it was determined that TT reduced anxiety level and improved sleep quality in individuals with chronic obstructive pulmonary disease. The Clinical Trial Registration Number: NCT04842903. * EFFECT OF THERAPEUTIC TOUCH ON DAYTIME SLEEPINESS, STRESS AND FATIGUE AMONG STUDENTS OF NURSING AND MIDWIFERY: A RANDOMIZED SHAM-CONTROLLED TRIAL 2021, Complementary Therapies in Clinical Practice Show abstractNavigate Down This study was conducted to assess the effect of therapeutic touch on stress, daytime sleepiness, sleep quality and fatigue among students of nursing and midwifery. 96 students were randomized into three groups: the therapeutic touch (TT) group, the sham therapeutic touch (STT) group, and the control group. In this randomized sham-controlled study, the TT group was subjected to therapeutic touch twice a week for four weeks with each session lasting 20 min. When the TT group was compared to the STT and control groups following the intervention, the decrease in the levels of stress (p < 0.001), fatigue (p < 0.001) and daytime sleepiness (p < 0.001), and the increase in the sleep quality (p < 0.001) were found to be significant. It was found that TT, which is one form of complementary therapy, was relatively effective in decreasing the levels of stress, fatigue and daytime sleepiness, and in increasing the sleep quality of university students of nursing and midwifery. * A RAPID EVIDENCE ASSESSMENT OF RECENT THERAPEUTIC TOUCH RESEARCH 2021, Nursing Open * WHAT INFLUENCE DOES THE THERAPEUTIC TOUCH HAVE ON BREAST CANCER? 2021, Medicina Interna de Mexico * PREDICTORS AND QUALITY OF LIFE IN PATIENTS WITH RADIODERMATITIS: A LONGITUDINAL STUDY 2021, ACTA Paulista de Enfermagem RECOMMENDED ARTICLES (6) * Research article PROSPECTIVE EVALUATION OF SEVERE SKIN TOXICITY AND PAIN DURING POSTMASTECTOMY RADIATION THERAPY International Journal of Radiation Oncology*Biology*Physics, Volume 91, Issue 1, 2015, pp. 157-164 Show abstractNavigate Down To prospectively capture acute toxicities and pain associated with postmastectomy radiation therapy (PMRT), to analyze patient and treatment risk factors for severe side effects. Women referred for PMRT were prospectively enrolled and assessed weekly during and after radiation therapy. The endpoint included severe National Cancer Institute Common Terminology Criteria for Adverse Effects grade 3 moist desquamation, other skin symptoms, and pain. Of 257 patients, 73 (28.4%) experienced extensive moist desquamation, 84 (32.7%) Common Terminology Criteria for Adverse Effects skin toxicity grade 3, and 57 (22.2%) a pain impacting on daily life activities. Among symptoms only grade 3 moist desquamation was significantly associated with severe pain (P<.001). On multivariate analysis, smoking, high-energy photons, and skin bolus were significantly associated with severe moist desquamation. Skin toxicity doubled for smokers, with 40% severe pain, 48% grade 3 moist desquamation, and 64% grade 3 skin toxicity. Without skin bolus 4.2% had severe pain, none moist desquamation, and 2.1% grade 3 skin toxicity. When skin bolus was used on alternate days, the frequency increased to 15% for pain, 22% for moist desquamation, and 26% for grade 3 skin toxicity. When bolus was used daily, 32% had pain, 41% moist desquamation, and 47% grade 3 skin toxicity. Symptoms peaked 1 to 2 weeks after the end of PMRT. The present cohort study suggests excessive radiation toxicity after PMRT. Among factors associated with an increase of toxicity are smoking habits and the use of skin bolus. * Research article IN SILICO INSTRUMENTAL RESPONSE CORRECTION IMPROVES PRECISION OF LABEL-FREE PROTEOMICS AND ACCURACY OF PROTEOMICS-BASED PREDICTIVE MODELS Molecular & Cellular Proteomics, Volume 12, Issue 8, 2013, pp. 2324-2331 Show abstractNavigate Down In the analysis of proteome changes arising during the early stages of a biological process (e.g. disease or drug treatment) or from the indirect influence of an important factor, the biological variations of interest are often small (∼10%). The corresponding requirements for the precision of proteomics analysis are high, and this often poses a challenge, especially when employing label-free quantification. One of the main contributors to the inaccuracy of label-free proteomics experiments is the variability of the instrumental response during LC-MS/MS runs. Such variability might include fluctuations in the electrospray current, transmission efficiency from the air–vacuum interface to the detector, and detection sensitivity. We have developed an in silico post-processing method of reducing these variations, and have thus significantly improved the precision of label-free proteomics analysis. For abundant blood plasma proteins, a coefficient of variation of approximately 1% was achieved, which allowed for sex differentiation in pooled samples and ≈90% accurate differentiation of individual samples by means of a single LC-MS/MS analysis. This method improves the precision of measurements and increases the accuracy of predictive models based on the measurements. The post-acquisition nature of the correction technique and its generality promise its widespread application in LC-MS/MS-based methods such as proteomics and metabolomics. * Research article TURKISH WOMEN'S KNOWLEDGE AND VIEWS REGARDING MOTHER'S MILK BANKING Collegian, Volume 21, Issue 3, 2014, pp. 239-244 Show abstractNavigate Down The main aim of the study was to determine the knowledge and views of Eastern Anatolian women towards mother's milk banking. The descriptive research was conducted between March and May 2009. The study population comprised 350 married women aged between 15 and 49 years who gave birth and who were registered with a family health center in Erzurum, Turkey. The data were collected by a questionnaire form. The questionnaire form included open-ended and closed questions regarding the descriptive characteristics and about knowledge and views of mothers on milk banking. The questionnaire form was completed by the women individually. Of the women surveyed, 90.6% indicated they had not previously heard anything about breast milk banking, 64.0% said that they could donate their milk, 36.3% stated it constituted a problem from a religious aspect, and 28.9% said it leads to social and moral problems. The hospital and maternity authorities may consider establishing a “milk mother file”. This report addresses the first step in raising awareness of the valuable contribution of donor milk to babies and the organization of human milk donation for use in a neonatal intensive care unit. * Research article MANAGEMENT OF ACUTE RADIATION DERMATITIS: A REVIEW OF THE LITERATURE AND PROPOSAL FOR TREATMENT ALGORITHM Journal of the American Academy of Dermatology, Volume 81, Issue 2, 2019, pp. 558-567 Show abstractNavigate Down Radiation dermatitis is a common sequela of radiation therapy; up to 95% of patients will develop moderate-to-severe skin reactions. No criterion standard currently exists for the treatment of acute radiation-induced skin toxicity. It is therefore imperative to develop a greater understanding of management options available to allow clinicians to make informed decisions when managing radiation oncology patients. This literature review discusses the topical agents that have been studied for the treatment of acute radiation dermatitis, reviews their mechanisms of action, and presents a treatment algorithm for clinicians managing patients experiencing radiation dermatitis. * Research article CHARACTERIZING THE EFFECTS OF RADIATION DERMATITIS ON QUALITY OF LIFE: A PROSPECTIVE SURVEY-BASED STUDY Journal of the American Academy of Dermatology, Volume 86, Issue 1, 2022, pp. 161-163 * Research article CLOSING THE GAP BETWEEN RESEARCH AND PRACTICE: IS IT THE KEY TO INCREASING THE IMPACT OF CAM RESEARCH? Complementary Therapies in Medicine, Volume 23, Issue 4, 2015, pp. 635-636 View full text Copyright © 2014 Elsevier Ltd. All rights reserved. * About ScienceDirect * Remote access * Shopping cart * Advertise * Contact and support * Terms and conditions * Privacy policy We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V. ScienceDirect® is a registered trademark of Elsevier B.V.